pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·2h ago·1 min read
save

Humana tops 2027 Medicare Advantage star ratings as insurers face $13 billion in bonus payouts and legal challenges

Oct 9, 2026·read at STAT ↗RegulatoryNeutral

The Centers for Medicare & Medicaid Services released the 2027 star ratings for Medicare Advantage plans, with Humana emerging as the top‑scoring insurer.

Plans that achieve at least four out of five stars qualify for bonus payments, which together total about $13 billion each year for the industry. Nearly 71% of Medicare Advantage enrollees are already in plans that meet this threshold.

Not all insurers are satisfied with their scores. Alignment Healthcare announced it will consider legal action after its rating was lowered, a move that reflects growing frustration among carriers.

The new ratings underscore both the financial incentives tied to quality measures and the lingering uncertainty about how future metrics will be applied and how they will impact revenue streams.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Medicare Advantage star ratings trigger new bonuses, and uncertainty”

read at STAT ↗
529 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Life Biosciences Inc.ROCHE
topics
Duchenne Muscular Dystrophy

related stories

  • 2h agoSTAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drugSTAT
  • 1d agoSTAT+: Roche inks drug discovery deal with Chinese biotech, focused on molecular glue medicinesSTAT
  • 2d agoGenmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, moreBioSpace
  • May 8Spain readies for evacuations as a hantavirus-hit cruise ship heads for the Canary IslandsSTAT
  • May 8STAT+: Roche to buy PathAI for $750 millionSTAT